131 related articles for article (PubMed ID: 16910232)
1. Down syndrome with myelodysplasia of megakaryoblastic lineage.
Henderson R; Spence L
Clin Lab Sci; 2006; 19(3):161-4. PubMed ID: 16910232
[TBL] [Abstract][Full Text] [Related]
2. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
4. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
5. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome.
Tavil B; Cetin M; Tuncer M
Leuk Res; 2006 Feb; 30(2):222-4. PubMed ID: 16098587
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
Creutzig U; Ritter J; Vormoor J; Ludwig WD; Niemeyer C; Reinisch I; Stollmann-Gibbels B; Zimmermann M; Harbott J
Leukemia; 1996 Nov; 10(11):1677-86. PubMed ID: 8892666
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
8. Optimizing therapy for myeloid disorders of Down syndrome.
Webb DK
Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
Zipursky A; Thorner P; De Harven E; Christensen H; Doyle J
Leuk Res; 1994 Mar; 18(3):163-71. PubMed ID: 8139285
[TBL] [Abstract][Full Text] [Related]
10. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
11. [Megakaryoblastic leukemia and transient abnormal myelopoiesis with Down's syndrome].
Suda J; Eguchi M
Rinsho Ketsueki; 1988 Aug; 29(8):1200-6. PubMed ID: 2974493
[No Abstract] [Full Text] [Related]
12. Transient myelodysplasia in an infant with Down syndrome preceding acute megakaryoblastic leukemia: cytogenetic and immunophenotypic findings.
Rodrigues EF; da Costa ES; Land MG; Diamond HR; Ornellas MH; Abdelhay E; Fernandez Tde S
Cancer Genet Cytogenet; 2009 Jan; 188(1):54-6. PubMed ID: 19061782
[No Abstract] [Full Text] [Related]
13. Pro-inflammatory cytokinemia is frequently found in Down syndrome patients with hematological disorders.
Shimada A; Hayashi Y; Ogasawara M; Park MJ; Katoh M; Minakami H; Kitoh T; Kojima S; Kawa K; Kimura H
Leuk Res; 2007 Sep; 31(9):1199-203. PubMed ID: 17055049
[TBL] [Abstract][Full Text] [Related]
14. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
15. [Acute myelogenous leukemia with multilineage myelodysplasia, positive direct Coombs test, and elevated levels of platelet-associated IgG].
Kuroda H; Matsunaga T; Sakamaki S; Koike K; Terui T; Neda H; Ishitani K; Nobuoka A; Kida M; Watanabe H; Niitsu Y
Rinsho Ketsueki; 2007 May; 48(5):407-11. PubMed ID: 17571587
[TBL] [Abstract][Full Text] [Related]
16. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia With Unusual Immunophenotype.
Koulmane Laxminarayana SL; Kohli S; Agrohi J; Belurkar S
Cureus; 2023 Mar; 15(3):e35965. PubMed ID: 36911590
[TBL] [Abstract][Full Text] [Related]
18. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
19. Loss of the extra chromosome 21 in a patient with Down syndrome and myelodysplasia.
Tan D; Lau LC; Teng LM; Sane S; Lim TH; Tien SL
Cancer Genet Cytogenet; 2008 Jan; 180(1):79-82. PubMed ID: 18068540
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural and ultracytochemical differences between megakaryoblastic leukemia in children and adults. Analysis of 49 patients.
Eguchi M; Ozawa T; Sakakibara H; Sugita K; Iwama Y; Furukawa T
Cancer; 1992 Jul; 70(2):451-8. PubMed ID: 1319816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
